126 related articles for article (PubMed ID: 34053399)
1. Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting.
Jazić I; Liu X; Laird G
J Biopharm Stat; 2021 Jul; 31(4):507-522. PubMed ID: 34053399
[TBL] [Abstract][Full Text] [Related]
2. A multi-stage drop-the-losers design for multi-arm clinical trials.
Wason J; Stallard N; Bowden J; Jennison C
Stat Methods Med Res; 2017 Feb; 26(1):508-524. PubMed ID: 25228636
[TBL] [Abstract][Full Text] [Related]
3. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
Roig MB; Melis GG; Posch M; Koenig F
Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
[TBL] [Abstract][Full Text] [Related]
4. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
[TBL] [Abstract][Full Text] [Related]
5. A two-stage drop-the-losers design for time-to-event outcome using a historical control arm.
Abbas R; Wason J; Michiels S; Le Teuff G
Pharm Stat; 2022 Jan; 21(1):268-288. PubMed ID: 34496117
[TBL] [Abstract][Full Text] [Related]
6. A case study of an adaptive design for a clinical trial with 2 doses and 2 endpoints in a rare disease area.
Quan H; Xu Y; Chen Y; Gao L; Chen X
Pharm Stat; 2018 Nov; 17(6):797-810. PubMed ID: 30221446
[TBL] [Abstract][Full Text] [Related]
7. Extension of a conditional performance score for sample size recalculation rules to the setting of binary endpoints.
Bokelmann B; Rauch G; Meis J; Kieser M; Herrmann C
BMC Med Res Methodol; 2024 Jan; 24(1):15. PubMed ID: 38243169
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design.
Karanevich A; Meier R; Graw S; McGlothlin A; Gajewski B
Am Stat; 2019; 2019():. PubMed ID: 32981939
[TBL] [Abstract][Full Text] [Related]
9. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
Li Q; Lin J; Lin Y
Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
[TBL] [Abstract][Full Text] [Related]
10. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
Schmidli H; Bretz F; Racine A; Maurer W
Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
[TBL] [Abstract][Full Text] [Related]
11. Exact two-stage designs for phase II activity trials with rank-based endpoints.
Wilding GE; Shan G; Hutson AD
Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
[TBL] [Abstract][Full Text] [Related]
12. Accurate p-values for adaptive designs with binary endpoints.
Heritier S; Lloyd CJ; Lô SN
Stat Med; 2017 Jul; 36(17):2643-2655. PubMed ID: 28470713
[TBL] [Abstract][Full Text] [Related]
13. An Adaptive Staggered Dose Design for a Normal Endpoint.
Wu J; Menon S; Chang M
J Biopharm Stat; 2015; 25(4):731-56. PubMed ID: 24904986
[TBL] [Abstract][Full Text] [Related]
14. Probability monitoring procedures for sample size determination.
Huang Z; Chow SC
J Biopharm Stat; 2019; 29(5):887-896. PubMed ID: 31454274
[TBL] [Abstract][Full Text] [Related]
15. Conditional information and inference in response-adaptive allocation designs.
Lane A
Stat Med; 2022 Jan; 41(2):390-406. PubMed ID: 34747523
[TBL] [Abstract][Full Text] [Related]
16. Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint.
Quan H; Xu Y; Liu Y; Chen X
Contemp Clin Trials; 2024 Mar; 138():107467. PubMed ID: 38331382
[TBL] [Abstract][Full Text] [Related]
17. Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early.
Huang B; Giannini EH; Lovell DJ; Ding L; Liu Y; Hashkes PJ
Contemp Clin Trials; 2014 Jul; 38(2):204-12. PubMed ID: 24833067
[TBL] [Abstract][Full Text] [Related]
18. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
Chen YH; Li C; Lan KK
Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
[TBL] [Abstract][Full Text] [Related]
19. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
20. A small n sequential multiple assignment randomized trial design for use in rare disease research.
Tamura RN; Krischer JP; Pagnoux C; Micheletti R; Grayson PC; Chen YF; Merkel PA
Contemp Clin Trials; 2016 Jan; 46():48-51. PubMed ID: 26586608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
